Global Recombinant Vaccines Market to Surpass US$ 1,809.7 Million by 2030 - Coherent Market Insights

News provided by

Jun 22, 2022, 13:30 ET

SEATTLE, June 22, 2022 /PRNewswire/ -- According to Coherent Market Insights, the global recombinant vaccines market is estimated to be valued at US$ 1,116.1 million in 2022 and is expected to exhibit a CAGR of 6.2% during the forecast period (2022-2030).

Key Trends and Analysis of the Global Recombinant Vaccines Market:

Major players operating in market are focusing on adopting strategies such as product approvals, which is expected to drive market growth over the forecast period. For instance, in March 2022, CanSinoBIO, a company developing and manufacturing biological vaccine products, announced that its Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) (trade name: Convidecia) had been approved by the Ministry of Health, Malaysia and the Indonesian National Agency of Drug and Food Control as a heterologous booster.

Request Sample Copy of this Report @ https://www.coherentmarketinsights.com/insight/request-sample/455

Key Market Takeaways:

Global recombinant vaccines market is expected to exhibit a CAGR of 6.2% during the forecast period due to increasing prevalence of various infections such as hepatitis B. For instance, according to the World Health Organization Facts Sheet 2022, around 296 million people were living with chronic hepatitis B infection in 2019 globally.

Among product types, the subunit recombinant vaccines segment is expected to dominate segment growth over the forecast period, owing to increased patent applications and allowance to key players for subunit recombinant vaccines. For instance, in May 23, 2022, Soligenix, a late-stage biopharmaceutical company, announced that the United States Patent and Trademark Office (USPTO) had issued a notice of allowance for the patent application titled "Compositions and Methods of Manufacturing Trivalent Filovirus Vaccines." The candidate filovirus vaccines have been previously shown to protect non-human primates (NHPs) from subsequent infection, and represent the only recombinant subunit vaccines that have demonstrated efficacy against Zaire ebolavirus and other filoviruses in NHPs.

On the basis of disease types, the infectious disease segment is expected to dominate segment growth over the forecast period, owing to increasing prevalence of infectious diseases. For instance, according to the data provided by the Worldometers, a reference website that provides counters and real-time statistics for diverse topics, as of June 9, 2022, there were 539,081,058 total cases of COVID-19 worldwide.

Key players operating in the global recombinant vaccines market include Merck & Co., Inc., Novartis AG, Pfizer Inc., Sanofi, GSK plc., GC Biopharma, Bayer AG, Bharat Biotech, Serum Institute of India Pvt. Ltd., Sartorius AG, Johnson & Johnson Services, Inc., and Bio Farma.

Request for Customization @ https://www.coherentmarketinsights.com/insight/request-customization/455

Detailed Segmentation:

Global Recombinant Vaccines Market, By Product Type:

Subunit Recombinant Vaccines
Attenuated Recombinant Vaccines
Vector Recombinant Vaccines

Global Recombinant Vaccines Market, By Disease Type:

Infectious Disease
Cancer
Allergy
Others

Global Recombinant Vaccines Market, By End User:

Recombinant Human Vaccines
Animal Recombinant Vaccines Hospitals

Poultry
Companion Animal Vaccines
Livestock
Porcine
Aquaculture Vaccines

Global Recombinant Vaccines Market, By Region:

North America

By Country:

U.S.
Canada

Europe

By Country:

U.K.
Germany
Italy
France
Spain
Russia
Rest of Europe

Asia Pacific

By Country:

China
India
Japan
ASEAN
Australia
South Korea
Rest of Asia Pacific

Latin America

By Country:

Brazil
Mexico
Argentina
Rest of Latin America

Middle East & Africa

By Country:

GCC Countries
Israel
South Africa
Rest of Middle East & Africa

Buy this Complete Report Now @ https://www.coherentmarketinsights.com/insight/buy-now/455

Find more related trending reports below:

Prophylactic Human Vaccine Market, By Vaccine Technology (Live Attenuated Vaccines, Inactivated Vaccines, Toxoid Vaccines, Polysaccharide Vaccines, Conjugate Vaccines, and Recombinant Vaccines), and by Geography (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022-2028

Porcine Vaccines Market, by Technology (Inactivated Vaccines, Live Attenuated Vaccines, Toxoid Vaccines, Recombinant Vaccines, Conjugate Vaccines , and DNA Vaccines) By Disease Indication (Diarrhea, Swine Influenza, Arthritis, Bordatella Rhinitis, Porcine Reproductive and Respiratory Virus (PRRSV), Porcine Circovirus Associated Disease (PCVAD), and Others) By End User (Veterinary Hospitals and Hog/Pig Production Farm) and By Geography - Global Industry Insights, Trends, Outlook, and Opportunity Analysis, 2022-2028

Adult Vaccines Market - by Vaccine (Influenza, Tetanus/Diphtheria/Pertussis, Varicella, Human Papillomavirus, Zoster, Measles/mumps/Rubella, Pneumococcal, Hepatitis, and Others), by Vaccine Type (Monovalent and Multivalent), by Technology (Live Attenuated Vaccines, Inactivated Viral or Bacterial Vaccines, Toxoid Vaccines, Recombinant Vaccines, and Conjugate Vaccines), and by Region - Global Industry Insights, and Forecast till 2025

About Us:

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having sales office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 57 countries worldwide. We create value for clients through our highly reliable and accurate reports. We are also committed in playing a leading role in offering insights in various sectors post-COVID-19 and continue to deliver measurable, sustainable results for our clients.

Contact Us:

Mr. Shah
Senior Client Partner – Business Development
Coherent Market Insights
Phone:
US: +1-206-701-6702
UK: +44-020-8133-4027
Japan: +81-050-5539-1737
India: +91-848-285-0837
Email: [email protected]
Website: https://www.coherentmarketinsights.com
Follow Us: LinkedIn | Twitter